Post-Genomics Blog

Forging a connection between research and clinical applications.

Genotyping Tools

Genotyping Tools

June 8-9, 2009
The Fairmont Hotel
San Francisco, CA

The genetic scientific community is exploding with new robust tools which explore the connections between genotypes and phenotypes. The falling prices from developing to mature genotyping platforms, result in abundant data to interrogate and analyze. In addition, as more detailed clinical classification of patients is performed, stronger genetic associations of complex diseases are discovered. The new technical developments that enable the association of genes with disease, as well as practical examples of how these techniques are used is the emphasis of Cambridge Healthtech Institute’s Second Annual Genotyping Tools: Sequencing to SNPs . . . Strategies to Success. Learn from savvy, seasoned researchers as they share their scientific strategies and success.

Pharmacogenomics Knowledge Base, PharmGKB (R24)

Pharmacogenomics Knowledge Base, PharmGKB (R24)

Purpose. The purpose of this funding opportunity issued by NIGMS is to enable new and renewal applications to compete for the Pharmacogenetics and Pharmacogenomics Knowledge Base, PharmGKB (, which will be renamed the Pharmacogenomics Knowledge Base. PharmGKB is being developed to serve the needs of the entire research community in pharmacogenomics. Optimally, the knowledge base PharmGKB will present complete, comprehensive, and current knowledge in pharmacogenomics, backed by the critical datasets (which may be archived elsewhere) and the most compelling literature. There are informatics challenges to managing and integrating large and disparate sets of information, and a compelling resource should be easily used and extremely valuable to stakeholders trying to advance the field of pharmacogenomics and its implementation. The ultimate goal of pharmacogenomics is to guide appropriate therapeutic choices, and PharmGKB should support and extend modern research approaches to achieve this goal. Previously, PharmGKB was a component of the Pharmacogenetics Research Network; now the network is the subject of another funding opportunity announcement (Pharmacogenomics Research Network, RFA-GM-10-001, PharmGKB is being renewed separately as a R24 in order to enable the knowledge base to be developed to clearly serve the needs of the entire research community in pharmacogenomics.

Key Dates
Release Date: March 5, 2009
Letters of Intent Receipt Date: May 2, 2009
Application Receipt Dates: June 2, 2009
Peer Review Date: November 2009
Council Review Date: January 2010
Earliest Anticipated Start Date: April 1, 2010
Additional Information To Be Available Date (Url Activation Date): March 1, 2009
Expiration Date: June 3, 2009


March 17-19, 2009
Hilton San Diego Resort
San diego, California

NEXT-GENERATION SEQUENCING is driving growth within the basic and biomedical research communities as rapidly as the bases are being sequenced. All agree, however, that with the implementation of any new technology there is a balancing act of cost-quality-quantity. The potential applications are as numerous as the samples to be analyzed. Each next-generation platform is optimized for specific sequencing applications. Cambridge Healthtech Institute’s Third Annual Next-Generation Sequencing offers an unparalleled opportunity to compare and contrast the next-generation sequencing platforms to best suit your research needs.

Translating Genomic Knowledge

Translating Genomic Knowledge -
Biological Discovery to Clinical Utility

June 9-10, 2009
The Fairmont Hotel | San Francisco, CA

The march of molecular genomics is progressing from the laboratory to the clinic. Within the pharmaceutical industry, applications of clinical genomics promises to enhance the discovery of drug response markers, reduce the size and expense of clinical drug trials, and provide tools for addressing regulatory approval issues. All agree that applying biological knowledge through prospective genotyping early in clinical trials is necessary, but putting the theory into practice remains a bottleneck. Cambridge Healthtech Institute’s Translating Genomic Knowledge: Biological Discovery to Clinical Utility expounds the driving factors that are encouraging pharmacogenetic strategy development in the pharmaceutical industry.

Molecular Medicine Tri-Conference

Molecular Medicine Tri-Conference

February 25-27, 2009
San Francisco, CA
Moscone North Convention Center

As the need for new technologies, improved strategies and competitive intelligence becomes ever more acute, CHI’s flagship event, the MOLECULAR MEDICINE TRI-CONFERENCE provides the breadth and depth of information critical to your organization’s success. The 2009 event includes ELEVEN parallel tracks that provide compelling and in-depth insight into the future of molecular medicine. These tracks add up to an indispensable conference for professionals grappling with the challenges of delivering 21st century medicine.




November 19-22, 2008
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY 11724-2213

This conference is the sixth in the series of joint Cold Spring Harbor/ Wellcome Trust conferences on Pharmacogenomics held in Hinxton, UK and Cold Spring Harbor in alternate years. The 2008 conference will be held at Cold Spring Harbor, beginning on the evening of Wednesday November 19, 2008 and ending with the banquet on Saturday evening November 22, with normal departure on Sunday morning.

Characterizing the Blood Stem Cell Niche (R01)

Characterizing the Blood Stem Cell Niche (R01)

Purpose. This FOA issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, solicits Research Project Grant (R01) applications in a specific area of stem cell research, the blood stem cell niche, an area critical to advancing stem cell biology and its applications to cellular therapeutics including hematopoietic stem cell transplantation. This FOA is being initiated to foster collaborative research projects and insightful approaches to dissect the cellular components and factors involved in the hematopoietic stem cell niche. Development of conditional genetic knock-out models to test the role of factors in specific cell lineages and imaging technology to facilitate following stem cell engraftment in the niche in vivo are integral to this initiative.

Key Dates
Release/Posted Date: October 17, 2008
Opening Date: December 15, 2008 (Earliest date an application may be submitted to
Letters of Intent Receipt Date(s): December 8, 2008
NOTE: On-time submission requires that applications be successfully submitted to no later than 5:00 p.m. local time (of the applicant institution/organization).Application Due Date(s): January 6, 2009
Peer Review Date(s): April/May 2009
Council Review Date(s): May 2009
Earliest Anticipated Start Date(s): July 1, 2009
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: January 7, 2009

The Stem Cell Congress

The Stem Cell Congress (Fourth Annual)

February 25-27, 2009
San Francisco, California

Moscone North Convention Center

Track 3 of the Molecular Medicine Tri-Conference
Explore cell-based therapeutics including the latest advances in stem cell therapies

Biomarkers Europe

Biomarkers Europe

10-11 November 2008
Vienna, Austria

  • Clinical Biomarkers
  • Pharmacogenomics
  • Biomarker Assay Development
  • Biomarkers in Clinical Pharmacology
  • Biomarkers for Patient Selection
  • Toxicity Biomarkers
  • ‘Omic’ Biomarkers
  • Regulatory Perspective
  • Revolutionary Genome Sequencing Technologies – The $1000 Genome (R01)

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (R01)

    Purpose: The National Human Genome Research Institute (NHGRI) solicits R01 grant applications to develop novel technologies that will enable extremely low-cost, high quality DNA sequencing. The goal of this initiative is to reduce the cost of sequencing a mammalian-sized genome to approximately $1000. Applicants may propose to develop full-scale sequencing systems or to investigate challenges underlying key system components. Exploration of methods other than those currently being pursued as potential $1,000 genome technologies are particularly encouraged. High-risk/high-payoff proposals are appropriate to achieve the goals of this FOA by approximately 2014

    Also see the following related funding initiatives:

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (R21)

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (SBIR [R43/R44])

    Revolutionary Genome Sequencing Technologies – The $1000 Genome (STTR [R41/R42])

    « Previous PageNext Page »
    Website by Visual Flavors
    Valid XHTML 1.0 Transitional
    Valid CSS!
    We subscribe to the HONcode principles of the HON Foundation. Click to verify.